In a hospital-based case/control study, 195 subjects with PCa and 250 healthy controls were investigated for the association of COX-2 -765 G>C (rs20417) and +8473 T>C (rs5275) promoter polymorphism with PCa susceptibility using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method.
In a hospital-based case/control study, 195 subjects with PCa and 250 healthy controls were investigated for the association of COX-2 -765 G>C (rs20417) and +8473 T>C (rs5275) promoter polymorphism with PCa susceptibility using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method.
Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association between each polymorphism and breast cancer risk under the codominant model, dominant model, and recessive model, respectively (nine studies with 6,968 cases and 9,126 controls for rs5275; three studies with 2,901 cases and 3,463 controls for rs20417; two studies with 5,551 cases and 6,208 controls for rs5277).
Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association between each polymorphism and breast cancer risk under the codominant model, dominant model, and recessive model, respectively (nine studies with 6,968 cases and 9,126 controls for rs5275; three studies with 2,901 cases and 3,463 controls for rs20417; two studies with 5,551 cases and 6,208 controls for rs5277).
We found no evidence that rs20417</span> alters prostate cancer</span> risk (odds</span> ratio (OR(CC & GC v GG)=1.05, 95% confidence interval (CI)=0.91-1.20).
We found no evidence that rs20417</span> alters prostate cancer</span> risk (odds</span> ratio (OR(CC & GC v GG)=1.05, 95% confidence interval (CI)=0.91-1.20).
We investigated five variants (rs5788, rs1330344, rs3842788, rs20417, and rs689466) of two COX genes in order to explaining the association between these polymorphisms and we also investigated the association between these variants and ischemic stroke risk to determine whether gene-gene interaction between these genes increases the susceptibility of ischemic stroke or its subtypes.
In the subgroup analyses stratified by ethnicity, the COX-2 -1195G/A, -765G/C, and +8473T/C were all associated with an increased HCC risk in Asian populations (rs689466 A vs. G: OR = 1.346, P = 0.001, 95% CI: 1.137-1.595, I<sup>2</sup> = 0.0%, P<sub>heterogeneity</sub> = 0.869; rs20417 CC vs. GG + GC: OR = 3.069, P = 0.013, 95% CI: 1.265-7.447; rs5275 CC vs. TT + TC: OR = 1.626, P = 0.020, 95% CI: 1.079-2.452, I<sup>2</sup> = 0.0%, P<sub>heterogeneity</sub> = 0.495).
In the subgroup analyses stratified by ethnicity, the COX-2 -1195G/A, -765G/C, and +8473T/C were all associated with an increased HCC risk in Asian populations (rs689466 A vs. G: OR = 1.346, P = 0.001, 95% CI: 1.137-1.595, I<sup>2</sup> = 0.0%, P<sub>heterogeneity</sub> = 0.869; rs20417 CC vs. GG + GC: OR = 3.069, P = 0.013, 95% CI: 1.265-7.447; rs5275 CC vs. TT + TC: OR = 1.626, P = 0.020, 95% CI: 1.079-2.452, I<sup>2</sup> = 0.0%, P<sub>heterogeneity</sub> = 0.495).
The high-risk interactive genotypes of rs20417, rs1371097 and rs2317676 were independently associated with primary adverse outcome of RIS, MI, and death after acute IS.
In the Brazilian cohort, rs20417 polymorphism was associated with both stroke (P = 5 × 10(-6)) and decreased PGE2 levels (P = 4 × 10(-5)); similarly, Chagas was associated with stroke (P = 4 × 10(-3)) and decreased PGE2 levels (P = 7 × 10(-3)).
Finally, we identified genetic variants in COX-2 (haplotype composed of rs2383515 G, rs5277 G, rs5275 T, and rs2206593 A) associated with post-treatment pain after endodontic treatment (P = .025).
Among patients with previous coronary artery disease (CAD), rs20417 carriers had a stronger protective effect on risk of major adverse events when compared with individuals without previous CAD (interaction P-value: 0.015).
Our results showed that the Cox-2 rs20417 (-765 G/C) polymorphism was not associated with HCC risk in the studied genetic contrast modes (C vs. G, GC vs. GG, and CC + GC vs. GG).
Carriage of the rs20417</span> minor allele was associated with a decreased risk of major CVD outcomes (OR = 0.78, 95% CI: 0.70-0.87; P = 1.2 × 10(-5)).
Similarly, no significant association of the Cox-2 rs5275 (+ 8473 T/C) polymorphism and HCC risk was found under any of the studied contrasts (C vs. T, TC vs. TT, CC vs. TT, CC + TC vs. TT, CC vs. TC + TT).
Therefore, the present study was taken up to investigate the role of -765G/C polymorphism (rs20417) in the cyclooxygenase-2 (COX-2) gene with AR in stroke patients.